Q-omics provides the consensus-scored PRIM2 profile across patient tissues and cancer cell-line models. PRIM2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PRIM2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PRIM2 protein abundance shows 26,334 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, HNSC, and LSCC as cancer lineages where PRIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRIM2 survival associations across molecular data types. PRIM2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRIM2 RNA expression–survival associations across cancer types. High PRIM2 expression shows unfavorable associations in MESO, ACC, KIRP, LIHC and PAAD, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for PRIM2 RNA expression.
This table summarizes PRIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRIM2 shows higher tumor expression in HNSC, KIRC, KIRP, LUAD, STAD and BLCA. The HNSC box plot shows higher PRIM2 RNA expression in tumor versus normal tissue (log2 FC = +1.497, t-test p < 0.001).
This table shows molecular features associated with PRIM2 in patient tissues and cancer cell lines. In patient samples, PRIM2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
